ReviewFrontiers in immunology2023
State of the art in childhood nephrotic syndrome: concrete discoveries and unmet needs.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Current status and research hotspots of pediatric nephrotic syndrome: a bibliometric analysis (2011-2025).Frontiers in pediatrics · 2026Pooled it
- Urinary leukotriene E4 for predicting steroid sensitivity in children with nephrotic syndrome: an observational cohort study.Pediatric nephrology (Berlin, Germany) · 2026Observational
- Treatment outcomes and ongoing pediatric trials in steroid-resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Review
- Safety and Effectiveness of Daratumumab in Recurrent and De Novo Focal Segmental Glomerulosclerosis After Kidney Transplant.Kidney medicine · 2026Article
- Shared hub genes in membranous nephropathy and kidney renal clear cell carcinoma: investigating molecular overlap and tumor progression.Discover oncology · 2025Article
- Causal association of circulating immune cells with nephrotic syndrome: evidence from a two-sample Mendelian randomization study.International urology and nephrology · 2025Article
- Screening core genes for minimal change disease based on bioinformatics and machine learning approaches.International urology and nephrology · 2025Article
- Icariin ameliorates minimal change disease by regulating the mitochondrial dysfunction pathway: an integrated strategy of network pharmacology, bioinformatics, and experimental validation.Frontiers in pharmacology · 2025Article
- Observation of rituximab as initial treatment in patients with minimal change disease- a retrospective study.Frontiers in immunology · 2025Article
- Rituximab Administration to Treat Nephrotic Syndrome in Children: 2-Year Follow-Up.Biomedicines · 2024Article
- Difficult-to-Treat Nephrotic Syndrome in Childhood-Global Depletion of B-Cells.Kidney international reports · 2024Article
- Crohn's disease after multiple doses of rituximab treatment in a child with refractory nephrotic syndrome and anFrontiers in pediatrics · 2024Article
- Case report: Early onsetFrontiers in pediatrics · 2023Article
- Epidemiology of Pediatric Nephrotic Syndrome: Real-World Data from Brazil.Glomerular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nephrotic syndrome (NS) is a clinical entity characterized by proteinuria, hypoalbuminemia, and peripheral edema. NS affects about 2-7 per 100,000 children aged below 18 years old yearly and is classified, based on the response to drugs, into steroid sensitive (SSNS), steroid dependent, (SDNS), multidrug dependent (MDNS), and multidrug resistant (MRNS). Forms of NS that are more difficult to treat are associated with a worse outcome with respect to renal function. In particular, MRNS commonly progresses to end stage renal failure requiring renal transplantation, with recurrence of the original disease in half of the cases. Histological presentations of NS may vary from minimal glomerular lesions (MCD) to focal segmental glomerulosclerosis (FSGS) and, of relevance, the histological patterns do not correlate with the response to treatments. Moreover, around half of MRNS cases are secondary to causative pathogenic variants in genes involved in maintaining the glomerular structure. The pathogenesis of NS is still poorly understood and therapeutic approaches are mostly based on clinical experience. Understanding of pathogenetic mechanisms of NS is one of the 'unmet needs' in nephrology and represents a significant challenge for the scientific community. The scope of the present review includes exploring relevant findings, identifying unmet needs, and reviewing therapeutic developments that characterize NS in the last decades. The main aim is to provide a basis for new perspectives and mechanistic studies in NS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.